<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02896309</url>
  </required_header>
  <id_info>
    <org_study_id>NL44415.078.13</org_study_id>
    <nct_id>NCT02896309</nct_id>
  </id_info>
  <brief_title>The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity</brief_title>
  <acronym>BIC</acronym>
  <official_title>The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <brief_summary>
    <textblock>
      This study evaluates the effect of oral sodium bicarbonate treatment on the intrarenal
      renin-angiotensin-system in adult patients with a metabolic acidosis and chronic kidney
      disease. This treatment is compared to sodium chloride treatment, which serves as control for
      increased sodium-intake and no treatment, which serves as time-control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In chronic kidney disease (CKD), as glomerular filtration rate decreases, excretion of
      hydrogen ions fails, leading to progressive metabolic acidosis (arterial pH &lt; 7.35 and a
      serum bicarbonate concentration &lt; 22 meq/L). Metabolic acidosis enhances further progression
      of CKD. It is known that the intrarenal renin-angiotensin system (RAS) is stimulated during
      metabolic acidosis, but it's specific role in the renal response on changes in the acid-base
      balance is unknown. Correction of metabolic acidosis by administration of bicarbonate is a
      common intervention in patients with metabolic acidosis due to chronic kidney disease. It is
      proven to slow down progression of CKD. There is no knowledge on the effect this therapy has
      on the intrarenal RAS. Since acidosis does not change serum renin levels, and bicarbonate
      therapy has no effect on blood pressure, it seems to have no effect on the systemic RAS. The
      investigators hypothesize that bicarbonate therapy diminishes intrarenal RAS activity without
      affecting the systemic RAS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary renin concentration</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Sodium bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral sodium bicarbonate tablets three times daily 1000mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium chloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral sodium chloride capsules two times daily 1000mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sodium bicarbonate</intervention_name>
    <arm_group_label>Sodium bicarbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sodium chloride</intervention_name>
    <arm_group_label>Sodium chloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female adult (â‰¥18 years)

          -  chronic kidney disease stage 4, i.e. estimated glomerular filtration rate (MDRD) 15-30
             ml/min

          -  plasma bicarbonate concentration of 15-24 meq/L

        Exclusion Criteria:

          -  bicarbonate level &gt;24 meq/L or &lt;15 meq/L, the latter because in that case it seems
             highly recommended to start sodium bicarbonate suppletion and not to postpone this

          -  sodium bicarbonate use in the 1 month preceding the study

          -  heart failure

          -  liver cirrhosis

          -  blood pressure &gt;140/90 mmHg despite the use of 3 different antihypertensives

          -  a kidney transplant in situ

          -  a history of nonadherence to medication

          -  use of calcineurin inhibitors (these immunosuppressive drugs are known to induce
             metabolic acidosis and influence electrolytes and acid-base balance)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewout J Hoorn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ewout J Hoorn, MD, PhD</last_name>
    <email>e.j.hoorn@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dominique Bovee</last_name>
    <email>d.bovee@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid Holland</state>
        <zip>3015CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewout Hoorn, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009 Sep;20(9):2075-84. doi: 10.1681/ASN.2008111205. Epub 2009 Jul 16.</citation>
    <PMID>19608703</PMID>
  </reference>
  <reference>
    <citation>Ng HY, Chen HC, Tsai YC, Yang YK, Lee CT. Activation of intrarenal renin-angiotensin system during metabolic acidosis. Am J Nephrol. 2011;34(1):55-63. doi: 10.1159/000328742. Epub 2011 Jun 10.</citation>
    <PMID>21659740</PMID>
  </reference>
  <reference>
    <citation>Nagami GT. Role of angiotensin II in the enhancement of ammonia production and secretion by the proximal tubule in metabolic acidosis. Am J Physiol Renal Physiol. 2008 Apr;294(4):F874-80. doi: 10.1152/ajprenal.00286.2007. Epub 2008 Feb 20.</citation>
    <PMID>18287403</PMID>
  </reference>
  <reference>
    <citation>Henger A, Tutt P, Riesen WF, Hulter HN, Krapf R. Acid-base and endocrine effects of aldosterone and angiotensin II inhibition in metabolic acidosis in human patients. J Lab Clin Med. 2000 Nov;136(5):379-89.</citation>
    <PMID>11079465</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>September 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2016</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Ewout Hoorn</investigator_full_name>
    <investigator_title>Internist nephrologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Acidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

